Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
136 USD | -0,73% | -0,73% | -.--% |
28/06 | Johnson & Johnson rapporteert 'positieve' resultaten in de late fase van de studie naar myasthenia gravis | MT |
28/06 | Rybrevant-combo van J&J-afdeling krijgt goedkeuring van EU | MT |
Officiële publicaties
SEC Filing 10Q-2 | CO | |
SEC Filing 8K | CO | |
1st-half-year results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-1 | CO | |
Minutes of the general assembly | CO | |
SEC Filing 8K | CO | |
1st quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
Proxy Statments | CO | |
SEC Filing 10K | CO | |
SEC Filing 8K | CO | |
Slide show results | CO | |
Annual results | CO | |
Dividends | CO | |
Acquisition | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-3 | CO | |
Slide show Q3 | CO | |
SEC Filing 8K | CO | |
3rd quarter results | CO | |
SEC Filing 8K | CO |
- Beurs
- Aandelen
- Koers JNJ
- Koers JNJ
- Nieuws Johnson & Johnson
- Officiële publicaties